

1 **Full Title:** Risk of Incident Atrial Fibrillation in Women with a History of Hypertensive  
2 Disorders of Pregnancy: A Population-Based Retrospective Cohort Study

3 **Short Title:** AFib Risk Following Pregnancy Hypertension

4

5 **Authors:** Amy Johnston, PhD, CPH<sup>1,2</sup> ; William Petrcich, MSc<sup>3</sup>; Graeme N. Smith, MD  
6 PhD<sup>4</sup>; Deshayne B. Fell, PhD<sup>1,5</sup>; Peter Tanuseputro, MD MHSc<sup>6</sup>; Thais Coutinho, MD<sup>7\*</sup>;  
7 Jodi D. Edwards, PhD<sup>1-3\*</sup>

8

9 <sup>1</sup> School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario,  
10 Canada

11 <sup>2</sup>Brain and Heart Nexus Research Program, University of Ottawa Heart Institute, Ottawa,  
12 Ontario, Canada

13 <sup>3</sup>ICES, Ottawa, Ontario, Canada

14 <sup>4</sup>Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Kingston  
15 Health Sciences Centre, Queens University, Kingston, Ontario, Canada

16 <sup>5</sup>Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada

17 <sup>6</sup>Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The  
18 University of Hong Kong, Hong Kong SAR, China

19 <sup>7</sup>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA

20

21 \* Drs. Coutinho and Edwards share senior authorship of this manuscript.

22

23

24 **Corresponding Authors:**

25 Dr. Thais Coutinho

26 Mayo Clinic

27 Department of Cardiovascular Medicine

28 200 First St. SW

29 Rochester, Minnesota, United States 55905

30 **E-mail:** [coutinho.thais@mayo.edu](mailto:coutinho.thais@mayo.edu)

31

32 Dr. Jodi Edwards

33 University of Ottawa Heart Institute

34 H4100 - 40 Ruskin Street

35 Ottawa, Ontario, Canada K1Y 4W7

36 **E-mail:** [JEdwards@ottawaheart.ca](mailto:JEdwards@ottawaheart.ca)

37

38 **Total word count** (excluding Title Page, Abstract, References, Tables and Figures

39 Legends, Acknowledgements, & Disclosures): 5,242

40

41 **Abstract**

42 **Background:** Hypertensive disorders of pregnancy (HDP) are a major cause of maternal  
43 morbidity and mortality and are associated with acute cardiac events in the peripartum  
44 period, as well as cardiovascular disease (CVD) later in life. Despite the robust  
45 association between hypertension and atrial fibrillation (AFib), comparatively little is  
46 known about HDP and individual HDP subtypes as sex-specific risk factors for AFib.

47  
48 **Methods:** A population-based retrospective cohort study of 771,521 nulliparous women  
49 discharged for obstetrical delivery of their first live or stillborn singleton infant between  
50 2002-2017 in Ontario, Canada. Data were obtained from record-level, coded, and linked  
51 population-based administrative databases housed at ICES. Using competing risks Cox  
52 proportional hazards regression, we estimated crude and multivariable-adjusted cause-  
53 specific hazard ratios (csHRs) and 95% confidence intervals (CIs) for associations  
54 between history of any HDP—and its six subtypes—and AFib before death, as well as all-  
55 cause mortality without a prior AFib diagnosis.

56  
57 **Results:** Approximately 8% of subjects were diagnosed with HDP during the 16-year  
58 exposure accrual period. The total person-time of follow-up was 7,380,304 person-years,  
59 during which there were 2,483 (0.3%) incident AFib diagnoses and 2,951 (0.4%) deaths.  
60 History of any HDP was associated with an increased csHazard of both incident AFib and  
61 death without a prior AFib diagnosis [adjusted csHRs (95% CIs): 1.45 (1.28-1.64) and  
62 1.31 (1.16-1.47), respectively]. These associations were observed in relatively young  
63 women (median time-to-event: 7 years postpartum). Associations suggestive of a ‘dose-

64 response' relationship were also observed, whereby both HDP severity, and presence of  
65 pre-pregnancy chronic hypertension, were associated with higher rates of both outcomes.

66

67 **Conclusions:** People exposed to HDP in their first delivery have a significantly increased  
68 csHazard of incident AFib compared to their unexposed counterparts, with higher rates  
69 observed in subjects exposed to more severe *de novo* HDP diagnoses as well as chronic  
70 hypertension in pregnancy. Given the substantial morbidity and mortality burden of AFib  
71 in women, these findings underscore the critical importance of considering history of HDP  
72 in risk calculation/stratification for both arrhythmic and non-arrhythmic CVDs; improving  
73 population-based surveillance of traditional and female-specific CVD risk factors; and  
74 developing targeted prevention strategies aimed at reducing the occurrence and burden  
75 of HDP.

76

77 **Keywords:** Hypertensive disorders of pregnancy, atrial fibrillation, retrospective cohort,  
78 administrative data, cardio-obstetrics

79

80

81

82

83

## 84 **Clinical Perspective**

### 85 **What is new?**

- 86 • In this population-based retrospective cohort study of 771,521 nulliparous women,  
87 a history of hypertensive disorders of pregnancy (HDP) significantly increased the  
88 cause-specific hazard of incident atrial fibrillation (AFib) compared to women  
89 without HDP, even after adjustment for confounders, and this association was  
90 observed in relatively young women (median follow-up: 7 years postpartum).
- 91 • Associations suggestive of a ‘dose-response’ relationships were observed,  
92 whereby subjects with more severe *de novo* HDP diagnoses, as well as those with  
93 pre-pregnancy chronic hypertension, had higher cause-specific rates of AFib, with  
94 the highest rate observed in subjects exposed to chronic hypertension in  
95 pregnancy.

### 96 97 **What are the clinical implications?**

- 98 • These findings suggest that women with a history of any HDP—especially those  
99 with pre-pregnancy chronic hypertension—may benefit from closer monitoring for  
100 the early detection of AFib.
- 101 • Enhanced population-based surveillance of, and targeted strategies to prevent,  
102 HDP as a female-specific cardiovascular risk factor are needed to mitigate  
103 intermediate- and long-term cardiovascular disease risk associated with these  
104 adverse pregnancy conditions.

105

106

107

108 **Introduction**

109 Hypertensive disorders of pregnancy (HDP), which affect between 5 to 15% of all  
110 pregnancies,<sup>1, 2</sup> are a heterogeneous group of obstetrical complications with differing  
111 epidemiology, pathophysiology, and symptomatology.<sup>3</sup> They are a major cause of  
112 maternal and fetal/neonatal morbidity and mortality,<sup>4</sup> with several studies reporting  
113 associations between a history of HDP and acute cardiac events in the peripartum period,  
114 as well as cardiovascular disease (CVD), later in life.<sup>5, 6</sup>

115  
116 The pathophysiological mechanisms linking HDP and CVD remain unclear.<sup>7</sup> However,  
117 observed associations may be driven by an interplay of several pregnancy-related factors  
118 that act through both maternal (e.g., advanced maternal age, history of obstetrical  
119 complications) and placental pathways, combined with additional accumulated exposure  
120 to non-pregnancy-related risk factors over the life course.<sup>7</sup> HDP may also trigger or  
121 accelerate vascular ageing,<sup>8</sup> which could also contribute to existing pathological  
122 processes, or may itself be a driving mechanism for increased CVD risk.<sup>4</sup>

123  
124 Most published studies assessing CVD risk in people with a history of HDP have focused  
125 on non-arrhythmic cardiovascular outcomes (e.g., myocardial infarction, stroke, heart  
126 failure, and coronary artery disease).<sup>7, 9, 10</sup> However, the global prevalence of atrial  
127 fibrillation (AFib) has rapidly increased over the past three decades,<sup>11</sup> rising from 19  
128 million individuals in 1990 to 38 million in 2017 (100% increase).<sup>11</sup> Indeed, AFib is now  
129 considered the cardiovascular epidemic of the 21<sup>st</sup> century,<sup>12</sup> with the absolute burden of

130 the disease projected to rise by more than 60% by 2025,<sup>12</sup> underscoring the critical need  
131 to study AFib to better understand its unique risk factors.

132

133 Prior studies examining the association between HDP and incident AFib<sup>4, 13-16</sup> have  
134 typically considered AFib as part of a composite outcome<sup>13, 15</sup> or have focused solely on  
135 preeclampsia.<sup>15, 17, 18</sup> Further, most of these studies had relatively short (median) follow-  
136 up times (e.g., one,<sup>14</sup> two,<sup>17</sup> and seven<sup>19</sup> years), did not consider death as a competing  
137 risk, and failed to control for several important confounders. Further, despite evidence  
138 that HDPs may represent distinct disease phenotypes,<sup>7, 20</sup> which present with varying  
139 levels of acute severity, no studies have examined potential dose-response associations  
140 between distinct HDP subtypes [e.g., chronic hypertension in pregnancy, (*de novo*)  
141 gestational hypertension] and incident AFib.

142

143 Given the rising social, economic, and public health burden of AFib,<sup>11, 21</sup> and a growing  
144 body of evidence suggesting that females are more likely to be symptomatic,<sup>22</sup> report  
145 lower overall quality of life, experience greater functional impairment,<sup>23</sup> have a higher  
146 susceptibility to AFib as their blood pressure increases,<sup>24</sup> and are diagnosed later in the  
147 disease course compared to males,<sup>25</sup> more evidence is needed about the relationship  
148 between HDP and its subtypes as sex-specific risk factors for AFib.<sup>14</sup> To address these  
149 knowledge gaps, our *primary aim* was to examine the association between exposure to  
150 any HDP in a first singleton pregnancy and subsequent incident AFib using a competing  
151 risks analytic framework. Our *secondary aim* was to evaluate potential dose-response

152 relationships between the severity of HDP (based on specific HDP subtypes) and incident  
153 AFib using the same analytical approach.

154

## 155 **Methods**

156 This study followed published methodological guidance on assessing CVD risk in people  
157 with a history of HDP using administrative healthcare data.<sup>7</sup> We also used the REporting  
158 of studies Conducted using Observational Routinely-collected health Data (RECORD)  
159 statement<sup>26</sup> to guide study reporting. A copy of our completed RECORD checklist is  
160 provided in Table S1.

161

162 We acknowledge that both gender expression and biological sex exist on a spectrum and  
163 have striven to use gender neutral terminology as much as possible. When the terms  
164 women/woman and maternal are used this manuscript, they should be interpreted  
165 inclusively.

166

## 167 *Data Availability Statement*

168 The dataset used in this study is held securely in coded form at ICES. While legal data  
169 sharing agreements between ICES and data providers (e.g., healthcare organizations  
170 and government) prohibit ICES from making the dataset publicly available, access may  
171 be granted to those who meet pre-specified criteria for confidential access, available at  
172 [www.ices.on.ca/DAS](http://www.ices.on.ca/DAS) (email: [das@ices.on.ca](mailto:das@ices.on.ca)). The full dataset creation plan and  
173 underlying analytic code are available from the authors upon request, understanding that



174 the computer programs may rely upon coding templates or macros that are unique to  
175 ICES and are therefore either inaccessible or may require modification.

176

### 177 *Study Design and Setting*

178 This was a population-based retrospective cohort study of nulliparous women discharged  
179 from Ontario hospitals for obstetrical delivery of their first live or stillborn singleton infant  
180 between April 1, 2002 and December 31, 2017 (index date of cohort entry). Subjects were  
181 followed until they had an incident AFib diagnosis, a recorded death date, were no longer  
182 eligible for OHIP (i.e., migrated out of Ontario), or at the end of study follow-up (December  
183 31<sup>st</sup>, 2019), whichever came first.

184

185 Ontario is Canada's most populous province and provides essential medical services, in-  
186 hospital prescription drugs, and immunizations free of charge for all residents through the  
187 Ontario Health Insurance Program (OHIP). Data generated from the use of routine  
188 healthcare services are maintained at ICES. ICES is an independent, non-profit research  
189 institute whose legal status under Ontario's health information privacy law allows it to  
190 collect and analyze health care and demographic data, without consent, for health system  
191 evaluation and improvement.

192

### 193 *Data Sources*

194 We used data obtained from record-level, coded, population-based administrative  
195 databases that were linked using unique encoded identifiers and analyzed at ICES  
196 (Figure S1; details about each dataset are provided in Table S2). Briefly, demographic

197 information at index delivery (maternal date of birth, residential postal code) was obtained  
198 from the Registered Persons Database (RPDB), a population registry file of all people  
199 eligible for OHIP since 1991 and enables linkage with other data holdings at ICES. The  
200 mother-baby database (MOMBABY), which uses the Canadian Institutes for Health  
201 Information Discharge Abstract Database (CIHI-DAD) to link in-hospital maternal and  
202 infant delivery records, was used to obtain information about maternal parity as well as  
203 baby's sex, date of birth, birthweight, and gestational age at birth. Information about  
204 diagnoses and procedures from clinical encounters and were obtained from the National  
205 Ambulatory Care Reporting System (NACRS), OHIP, CIHI-DAD, and the Same Day  
206 Surgery (SDS) database, as well as several ICES-derived cohorts (Ontario Hypertension  
207 Dataset, Ontario Diabetes Dataset, Ontario Crohn's and Colitis Cohort, Ontario  
208 Rheumatoid Arthritis Dataset).

209  
210 We used the Ontario portion of the Immigration, Refugee and Citizenship Canada's  
211 (IRCC) permanent resident database to ascertain immigration status. Information about  
212 area-level socioeconomic status was ascertained using the Ontario Marginalization Index  
213 (ON-Marg; quintiles)<sup>27</sup> by linking residential postal codes (RPDB) with census data, and  
214 we used the Rural Index of Ontario (RIO) to determine subject rurality at index delivery.  
215 The postal code conversion file was used to convert subject postal codes to area-level  
216 quintiles.

217

218

219

220 *Subject Eligibility*

221 All adults aged  $\geq 18$  years who delivered their first live or stillborn infant at  $\geq 20$  weeks  
222 gestational age, or  $>500$ -gram birthweight, between April 1, 2002 and December 31, 2017  
223 (index date) were initially eligible for inclusion. Individuals were excluded if they were  $>55$   
224 years of age, not Ontario residents, had an invalid health card number, a recorded death  
225 date prior to their index date, were not eligible for OHIP coverage, or had  $<2$  years of  
226 continuous coverage, prior to cohort entry. People with a history of/ongoing AFib at the  
227 time of index delivery and those missing data required for ON-Marg ( $n = 8,587$ ; 1.1%)  
228 were also excluded. During the exposure accrual period, approximately 98% of all births  
229 in Ontario occurred in-hospital.<sup>28</sup>

230

231 *Study Variables*

232 A directed acyclic graph (DAG) illustrating the hypothesized relationships between study  
233 variables (i.e., primary exposure, outcome, relevant confounders) is shown in Figure S2.

234

235 *Primary and Secondary Exposures*

236 The primary exposure was a composite 'any HDP' variable defined as any diagnosis of  
237 gestational hypertension, chronic hypertension in pregnancy, preeclampsia, chronic  
238 hypertension with superimposed preeclampsia (superimposed preeclampsia), eclampsia,  
239 or unspecified HDP in subjects' first obstetrical delivery. Secondary exposures included  
240 each individual HDP within the composite HDP exposure.

241

242 No case-finding definitions/algorithms for ‘any HDP’, or individual HDP subtypes, have  
243 been validated on Ontario population-based administrative data. As such, each HDP  
244 exposure was identified by applying the best available, and most relevant, case-finding  
245 definition validated in other jurisdictions to each subject’s discharge abstract (Table S3).<sup>7</sup>

246 <sup>29</sup> We also searched for ‘unspecified’ HDP by looking for any International Classification  
247 of Disease, Tenth Revision (ICD-10) code beginning with O16 in each subject’s obstetrical  
248 discharge abstract.

249  
250 We employed a hierarchical ‘severity coding’ approach to exposure classification whereby  
251 any subject whose discharge abstract met the case-finding definition for >1 HDP subtype  
252 had their exposure status re-coded such that only their most severe diagnosis was  
253 recorded. Further details on the use of this approach are provided in Data Supplement  
254 S4.

255  
256 Outcome and Competing Risk

257 The primary outcome was incident AFib, which was identified using a case-finding  
258 definition previously validated in Ontario population-based administrative data (Table  
259 S4).<sup>30</sup> This algorithm has a reported specificity of 99%, and a positive predictive value of  
260 71%, for the identification of incident AFib in Ontario adults  $\geq 20$  years of age.<sup>30</sup> We did  
261 not differentiate between AFib type (i.e., paroxysmal, persistent, long-standing). The  
262 competing risk, all-cause death, was determined by the presence of a death date in the  
263 RPDB.

264

265 Confounders

266 We identified several risk factors for AFib that are also associated with, but not an effect  
267 of, HDP (*i.e.*, confounders)<sup>31</sup> based on input from clinical experts and evidence available  
268 from published literature.<sup>32-38</sup> Behavioural and clinical factors identified as potential  
269 confounders included: maternal age at delivery, pre-existing diabetes mellitus, polycystic  
270 ovary syndrome, sleep apnea, smoking, kidney disease, chronic immune-mediated  
271 inflammatory conditions, and pre-pregnancy obesity. We used ON-Marg material  
272 resources dimension<sup>27</sup> quintiles to control for potential confounding by area-level  
273 socioeconomic status.<sup>39, 40</sup> All confounders were treated as time-fixed and assessed only  
274 at baseline. Further details about the methods used to identify these conditions are  
275 summarized in Table S4.

276

277 Follow-up for Outcome and Competing Risk

278 Subjects were followed until they had an incident AFib diagnosis (outcome), a recorded  
279 death date in the RPDB (competing risk), were no longer eligible for OHIP, or at the end  
280 of study follow-up, whichever came first. All subjects who were eligible for OHIP, were still  
281 alive, and did not fulfil the algorithm for AFib by December 31<sup>st</sup>, 2019 were censored.

282

283 *Statistical Methods*

284 Descriptive Analyses

285 Baseline characteristics and comorbidities (*i.e.*, conditions present at any time prior to  
286 index delivery) are presented as medians (quartile (Q)<sub>3</sub> – Q<sub>1</sub>) and number affected (n),  
287 percentages (%) for categorical variables. We assessed differences in baseline

288 characteristics between HDP exposure status using absolute standardized differences  
289 (ASD). ASD >10% were considered indicative of potentially meaningful differences  
290 between the exposure and characteristic being assessed.<sup>41</sup> We also calculated the  
291 proportion of subjects diagnosed with each HDP subtype over the study period. In  
292 accordance with ICES privacy policies, small cells (counts <6) have been suppressed or  
293 combined to reduce the risk of reidentification.

294  
295 Crude and Multivariable Cause-Specific Cox Proportional Hazards Regression  
296 Prior to fitting statistical models, each study variable was assessed for missingness, the  
297 presence of extreme/influential values, and possibly erroneous data (as appropriate). Phi  
298 coefficients were used to assess the strength of correlation between dichotomous  
299 variables; coefficients of  $\geq 0.2$  were interpreted as at least moderately correlated  
300 variables.<sup>42</sup>

301  
302 Cause-Specific Cox Proportional Hazards Regression  
303 We used competing-risks Cox proportional hazards regression to compute crude and  
304 multivariable-adjusted cause-specific hazard ratios (csHRs), and accompanying 95%  
305 CIs, to assess the association between history of any HDP, and specific HDP subtypes  
306 and (a) incident AFib in those still alive during follow-up as well as (b) all-cause mortality  
307 in the absence of a prior AFib diagnosis.

308  
309 We fit separate models for incident AFib and all-cause mortality, treating subjects who  
310 died, or were diagnosed with AFib, as censored in each respective model. We also tested

311 for multiplicative interaction between HDP and material resources given known disparities  
312 in the burden of HDP and AFib according to socioeconomic status.<sup>43, 44</sup> Calendar time  
313 was used as the underlying time scale in all models.

314

315 For each cause-specific model, we used both graphical and formal statistical tests  
316 (Schoenfeld residuals and residual plots,<sup>45</sup> Kolmogorov-type supremum tests<sup>46</sup>) to assess  
317 whether the effect of each variable on the csHazard function was constant over time.<sup>47</sup> A  
318 2-sided p-value <0.05 was considered evidence that the variable being tested likely  
319 violated the PH assumption.<sup>46, 48</sup>

320

321 After visually assessing residual plots, and considering the results of formal statistical  
322 tests, the PH assumption was considered violated for gestational hypertension (AFib  
323 model only), as well as the covariates age (both cause-specific models) and material  
324 resources (mortality models only). As such, in AFib models for subjects exposed to  
325 gestational hypertension, we performed a time-segmented analysis by restricting follow-  
326 up time to >4.5 years post-delivery, as the PH assumption held for this follow-up period.  
327 In models assessing all-cause mortality, we stratified by material resources.<sup>49</sup> Final  
328 models included maternal age at delivery as a restricted cubic spline with five knots  
329 placed at the 5<sup>th</sup>, 27.5<sup>th</sup>, 50<sup>th</sup>, 72.5<sup>th</sup>, and 95<sup>th</sup> percentiles.<sup>50</sup>

330

### 331 Sensitivity Analyses

332 We carried out three sensitivity analyses: two were carried out to assess how (1)  
333 excluding subjects with certain pre-existing conditions (Table S5), and (2) restricting

334 follow-up times for observing AFib/mortality events, impacted effect estimates. A third  
335 sensitivity analysis assessed the potential impact of unmeasured confounding on the  
336 effect estimates generated (E-values). Further details are provided in Data Supplement  
337 S6.

338  
339 All analyses were carried out using SAS Enterprise Guide (Version 8.3, SAS Institute,  
340 Cary, NC). Forest plots were generated using the ggplot2 package<sup>51</sup> in RStudio (v.  
341 2023.12.1.402) to visualize effect estimates (95% CIs) and facilitate comparisons  
342 between HDP exposures.

343  
344 *Ethics Approval*  
345 The use of the data in this project is authorized under section 45 of Ontario's Personal  
346 Health Information Protection Act (PHIPA) and does not require review by a Research  
347 Ethics Board.

348  
349 **Results**

350 *Selection of Study Subjects*  
351 We identified 2,105,409 women discharged from an Ontario hospital for a potentially  
352 eligible obstetrical delivery between April 1, 2002 and December 31, 2017. After excluding  
353 non-Ontario residents, people <18 and >55 years of age, individuals with a recorded  
354 death date prior to their index date, <2 years of continuous OHIP eligibility, and a history  
355 of/ongoing AFib prior to or at index delivery, in addition to non-nulliparous women and  
356 subsequent deliveries of otherwise eligible women, subjects with multiple gestation first



357 pregnancies, and people with missing ON-Marg information, a total of 771,521 subjects  
358 were included in the study cohort (Figure 1).

359

### 360 *Baseline Maternal Characteristics at Study Entry*

361 Most maternal risk factors and adverse pregnancy outcomes were more prevalent in  
362 people with a history of HDP. However, only a moderate number of differences were  
363 considered potentially meaningful (ASD >10%); Table 1.

364

365 Individuals with a history of HDP in their first obstetrical delivery were older than those  
366 with no HDP diagnosis (ASD for median age, 13%) and were more likely to have pre-  
367 existing diabetes and hypertension. In contrast, subjects with a history of HDP were less  
368 likely to be an immigrant, to reside in an urban area, or in neighborhoods with the highest  
369 quintile of racialized and newcomer populations (Table 1). The prevalence of pre-existing  
370 cardiovascular and endocrine conditions at baseline was numerically equivalent to, or  
371 marginally higher in, subjects diagnosed with HDP (Table S6). Additional details related  
372 to baseline obstetrical characteristics are provided in Table S7.

373

### 374 *Hypertensive Disorder of Pregnancy Exposure Status and Incident Chronic Hypertension* 375 *Post-delivery*

376 Approximately 8% of study subjects were diagnosed with HDP during the 16-year  
377 exposure accrual period (79.7 per 1,000 deliveries, n=61,486). The most common  
378 diagnosis was gestational hypertension (52.4 per 1,000 deliveries, n=40,460); the least

379 common was eclampsia (1.1 per 1,000 deliveries, n=824). A total of 1,691 subjects had a  
380 diagnostic code for unspecified HDP (2.2 per 1,000 deliveries) (Figure 2).

381  
382 Nearly 5% (n= 36,507) of study subjects were diagnosed with incident chronic  
383 hypertension at some point after pregnancy during the follow-up period. It was especially  
384 prevalent in subjects diagnosed with gestational hypertension (n=6,486, 16%) and  
385 preeclampsia (n=2,030, 14%) in their index delivery.

386  
387 *Incidence Rates and Time to Event Analyses*

388 The total person-time of follow-up was 7,380,304 person-years (median follow-up 9.5  
389 years), during which there were 2,483 (0.3%) incident AFib diagnoses and 2,951 (0.4%)  
390 deaths. The crude cause-specific incidence rate (95% CI) of AFib ranged from 4.52 (3.96-  
391 5.08) per 10,000 person-years for gestational hypertension to 10.18 (7.13-13.24) per  
392 10,000 person-years for chronic hypertension in pregnancy. Crude mortality rates (95%  
393 CI) in those without a prior AFib diagnosis ranged from 4.59 (4.03-5.16) per 10,000  
394 person-years for gestational hypertension to 11.97 (6.29-17.66) per 10,000 person-years  
395 for superimposed preeclampsia; Table 2.

396  
397 The median age (Q1-Q3) of subjects with AFib was 30 (26-34 years), with 32% aged 40  
398 years or older at their time of diagnosis, and the median age of those who died was 29  
399 years (23-33 years), with 33% aged 40 years of age or older at their time of death. A total  
400 of 766,087 subjects were censored [n=26,926 (3.5%) due to a lapse in OHIP coverage;  
401 n= 739,161 (95.8%) at end of study].

402 When HDP exposure status was considered collectively (i.e., exposure to any HDP  
403 subtype), the median time to event was nearly identical for both AFib and all-cause  
404 mortality [7.1 years (2,574 days)] vs. [2,567 days (7.0 years)], respectively). However,  
405 when each HDP exposure was considered individually, there was considerable  
406 heterogeneity with respect to median time-to-event for both event types (Figure 3).  
407 Specifically, subjects diagnosed with preeclampsia had the shortest median time to an  
408 incident AFib diagnosis at approximately 5.5 years, while those diagnosed with eclampsia  
409 had the longest median time to an AFib diagnosis at approximately 11.8 years. Further,  
410 the median time to an incident AFib diagnosis was most similar between subjects  
411 diagnosed with unspecified HDP and chronic hypertension in pregnancy (6.1 and 6.4  
412 years, respectively), while the median time to death was most similar between those  
413 diagnosed with unspecified HDP and superimposed preeclampsia (8.7 and 8.3 years,  
414 respectively).

415

#### 416 *Cause-Specific Cumulative Incidence Curves*

417 Cause-specific cumulative incidence curves for incident AFib and all-cause mortality,  
418 stratified by HDP exposure status, are shown in Figure 4. Subjects with a history of any  
419 HDP in their first singleton delivery had a consistently higher incidence of AFib and all-  
420 cause mortality compared to their unexposed counterparts over the follow-up period;  
421 differences in these curves were apparent within approximately two years of the  
422 pregnancy. For all-cause mortality, clear differences in these curves occurred slightly later,  
423 at approximately three years post-delivery (Figure 4). Similar findings were noted for each  
424 HDP subtype (Figures S4, S5).

425 *Cause-Specific Hazard of AFib and All-Cause Mortality*

426 After adjusting for confounders, we found that a history of any HDP in a first obstetrical  
427 delivery was associated with a 45% increased csHazard of incident AFib (adjusted csHR  
428 1.45, 95% CI: 1.28-1.64), as well as an increased csHazard of death in subjects without  
429 a prior AFib diagnosis (adjusted csHR 1.31, 95% CI: 1.16-1.47) (Figures 5A and 5B,  
430 respectively).

431  
432 With respect to specific HDP subtypes, we found that a history of gestational  
433 hypertension, preeclampsia, and chronic hypertension in pregnancy were all associated  
434 with an increased csHazard of incident AFib [adjusted csHR (95% CI): 1.49 (1.25-1.78),  
435 1.53 (1.20-1.96), and 2.24 (1.55-3.23), respectively]; Figure 5A. While crude estimates  
436 indicated a significant cause-specific association between superimposed preeclampsia  
437 and incident AFib, the observed relationship was attenuated and no longer significant  
438 after multivariable adjustment (csHR 1.70, 95% CI: 0.84 to 3.43); Table S8. We also found  
439 that a history of preeclampsia, unspecified HDP, chronic hypertension in pregnancy, and  
440 superimposed preeclampsia were each independently associated with an increased  
441 csHazard of death in subjects without an AFib diagnosis [adjusted csHR (95% CI): 1.43  
442 (1.13-1.81), 1.91 (1.13-3.23), 2.04 (1.43-2.91), and 2.12 (1.20-3.78), respectively]; Figure  
443 5B. Crude estimates also indicated a significant cause-specific association between both  
444 gestational hypertension and eclampsia and all-cause mortality. However, these  
445 relationships were attenuated and no longer significant after multivariable adjustment  
446 [csHR (95% CI): 1.13 (0.97-1.31) and 1.91 (0.96-3.83), respectively]; Table S9.

447

448 *Dose-Response Relationships*

449 As summarized in Table 3, we identified associations suggestive of ‘dose-response’  
450 relationship whereby both the severity of *de novo* HDP diagnoses, and exposure to pre-  
451 pregnancy chronic hypertension, were associated with higher cause-specific rates of AFib  
452 and all-cause mortality. Specifically, a history of gestational hypertension in a first delivery  
453 showed the smallest significant cause-specific association with incident AFib [adjusted  
454 csHR (95% CI) 1.49 (1.25-1.78)] compared to more severe *de novo* HDP exposures, such  
455 as preeclampsia. However, a history of chronic hypertension in pregnancy was most  
456 strongly associated with incident AFib compared to all other HDP diagnoses, with an  
457 adjusted csHR (95% CI) of 2.24 (1.55-3.23). We also noted that chronic hypertension in  
458 pregnancy was more strongly associated with all-cause mortality without a prior AFib  
459 diagnosis compared to preeclampsia [csHR (95%CI) 2.04 (1.43-2.91) vs. 1.43 (1.13-  
460 1.81), a *de novo* diagnosis. Further, a history of exposure to both pre-pregnancy  
461 hypertension and preeclampsia (i.e., superimposed preeclampsia) in a first pregnancy  
462 showed the strongest cause-specific association with mortality compared to all other HDP  
463 subtypes (csHR 2.12, 95%CI: 1.20-3.78).

464

465 *Sensitivity Analyses*

466 When the observation period for incident AFib events and all-cause mortality was limited  
467 to >90 days post index delivery, the csHazard of AFib in subjects who were still alive  
468 during follow-up was attenuated slightly in those exposed to any HDP, chronic  
469 hypertension in pregnancy, and preeclampsia in their first obstetrical delivery. However,  
470 all estimates remained statistically significant. Similar results were found for estimates of

471 death without a prior AFib diagnosis (Table S10). Estimates obtained for models limited  
472 to >120 days of follow-up were similar to those limited to >90 days of follow up (not  
473 reported).

474  
475 When models were re-run after excluding subjects with baseline cardiovascular and  
476 endocrine conditions, most estimates remained essentially unchanged or were minimally  
477 attenuated (Table S10). The only exception was the estimate for subjects exposed to  
478 chronic hypertension in pregnancy, where the csHR for AFib increased slightly from 2.24  
479 (95% CI: 1.55-3.23) to 2.42 (95% CI: 1.63-3.59) after excluding subjects with these  
480 baseline conditions. Similar results were found for all-cause mortality without a prior AFib  
481 diagnosis after subjects with these pre-existing conditions were excluded from the  
482 analysis [adjusted csHR (95% CI): 2.05 (1.43-2.92) vs. 2.20 (1.51-3.19)].

483  
484 E-values indicated that effect estimates were generally robust to unmeasured  
485 confounding (Table S11). Specifically, for gestational hypertension, chronic hypertension  
486 in pregnancy, and preeclampsia, an unmeasured confounder would need to at least  
487 double the risk of AFib and be at least twice as prevalent in those with a history of these  
488 HDPs, to explain away the observed associations. Similarly, for chronic hypertension in  
489 pregnancy, preeclampsia, superimposed preeclampsia, and unspecified HDP, an  
490 unmeasured confounder would need to at least double the risk of mortality before a prior  
491 AFib diagnosis and be at least twice as prevalent in those with a history of these  
492 exposures, to explain away the observed associations.

493

494 **Discussion**

495 This population-based retrospective cohort study of 771,521 nulliparous women has three  
496 novel findings. First, a history of ‘any’ HDP is independently associated with an increased  
497 csHazard of both AFib and all-cause mortality, and these associations were observed in  
498 relatively young women (median time-to-event: 7 years postpartum). Second, a history of  
499 gestational hypertension, preeclampsia, and chronic hypertension in pregnancy are each  
500 independently associated with an increased csHazard of incident AFib, whereas a history  
501 of preeclampsia, unspecified HDP, chronic hypertension in pregnancy, and superimposed  
502 preeclampsia are each independently associated with an increased csHazard of all-cause  
503 mortality without a prior AFib diagnosis. Third, a dose-response relationship may exist  
504 within these associations, as both HDP severity, as well as the presence of pre-pregnancy  
505 chronic hypertension, were found to be associated with higher rates of both adverse  
506 outcomes.

507  
508 The pathophysiologic mechanism(s) underlying the observed associations are complex  
509 and multifactorial.<sup>7</sup> However, HDP and AFib share a number of important features,<sup>52</sup> such  
510 as cardiac remodelling,<sup>53</sup> endothelial dysfunction,<sup>54, 55</sup> and inflammation,<sup>56, 57</sup> which are  
511 likely central to the development of AFib in individuals with a history of HDP. This is further  
512 supported by evidence indicating that HDP-associated inflammation and endothelial  
513 dysfunction can persist well into the postpartum period,<sup>52, 54, 56</sup> or become permanent,<sup>58,</sup>  
514 <sup>59</sup> resulting in extensive changes to endothelial cell function in both small and large  
515 vessels.<sup>60, 61</sup> Indeed, recent work<sup>8</sup> also suggests that cardiovascular alterations  
516 associated with HDP lead to early vascular ageing, which could explain the increased

517 predisposition to AFib noted in individuals exposed to HDP in this study– especially given  
518 that AFib is typically associated with older age.

519

520 Only a limited number of cohort studies have reported significant associations between a  
521 history of HDP and incident AFib.<sup>4, 14, 16</sup> With respect to any HDP, we found a  
522 comparatively lower rate of incident AFib than that reported by Leon *et al.*,<sup>16</sup> who reported  
523 a nearly 2-fold higher adjusted hazard of AFib in people exposed to HDP after 9.3 median  
524 years of follow-up. In comparison, after 9.5 median years of follow-up, we found a 1.4-  
525 fold higher adjusted csHazard of AFib, and a 1.3-fold higher adjusted csHazard of all-  
526 cause mortality in those with a history of any HDP. A few factors could explain these  
527 findings.

528

529 First, although Leon *et al.*<sup>16</sup> controlled for some important confounders, such as maternal  
530 age and diabetes, several others (e.g., pre-pregnancy body mass index (BMI), tobacco  
531 use, kidney disease) were not accounted for. Second, their data were analyzed using  
532 conventional Cox models, which are carried out under the assumption of noninformative  
533 censoring.<sup>62</sup> However, in the presence of  $\geq 1$  competing risk,<sup>63</sup> this assumption is violated,  
534 and can result in upward-biased effect estimates.<sup>62, 64</sup> In this study, we accounted for a  
535 more robust set of confounders and used cause-specific Cox models to appropriately  
536 address competing risks, which may explain our comparatively lower adjusted HRs for  
537 both incident AFib and all-cause mortality.

538



539 Robust evidence suggests an association between history of HDP and risk of both CVD  
540 and mortality within the first decade following an affected pregnancy.<sup>65, 66</sup> A recently  
541 published study<sup>65</sup> reported a 1.2-fold increased risk of all-cause death in women <50  
542 years of age with a history of any HDP compared to their unexposed counterparts.  
543 Despite this, only one published study<sup>14</sup> reporting estimates of AFib risk in people  
544 exposed to HDP acknowledged the omission of mortality assessment as a study  
545 limitation.

546  
547 In alignment with previous work,<sup>65</sup> we found that a history of any HDP in a first obstetrical  
548 delivery was associated with a 30% increased rate of death without a prior AFib diagnosis  
549 after 9.5 years of follow-up. Importantly, the median age of subjects who died during the  
550 follow-up period was 29 years, with 67% of subjects being younger than 40 years of age  
551 when they died. Further, although both incident AFib and death were rare outcomes,  
552 death was slightly more common than AFib (2,951 vs. 2,483 respectively). These findings  
553 underscore the importance of considering mortality as a competing risk for non-fatal CVD  
554 outcomes in this relatively young population, as failure to do so could result in artificially  
555 inflated estimates of association.

556  
557 We identified associations suggestive of dose-response relationships whereby both HDP  
558 severity and the presence of pre-pregnancy chronic hypertension were associated with  
559 higher cause-specific rates of both AFib and all-cause mortality. While the increasing  
560 magnitude of these point estimates suggests a dose-response pattern, cautious  
561 interpretation is needed due to overlapping 95% confidence intervals and non-significant

562 estimates for specific diagnoses, likely due at least in part to insufficient power to examine  
563 specific associations among subtypes. Further, these associations did not directly align  
564 with our ‘hierarchical’ definition of HDP severity, which was assessed from the viewpoint  
565 of their acute clinical consequences for mother and fetus.<sup>7</sup> Specifically, during exposure  
566 classification, we considered chronic hypertension in pregnancy to be the second most  
567 severe HDP diagnosis. However, it was associated with the highest csHazard of AFib and  
568 second highest csHazard of mortality without a prior AFib diagnosis [adjusted csHR (95%  
569 CI) 2.24 (1.55-3.23) and 2.04 (1.43-2.91), respectively]. Indeed, if future studies  
570 assessing CVD risk in people with a history of HDP continue to examine HDP as a  
571 composite exposure or adopt a narrow definition of HDP severity, critical dose-response  
572 associations may remain unidentified.<sup>7</sup>

573  
574 Despite the obvious time-varying nature of HDP and CVD risk factors, most prior work  
575 assessing CVD risk in people with a history of HDP has employed a first pregnancy, time-  
576 fixed, approach to exposure ascertainment and data analysis.<sup>67</sup> In this study, we also  
577 defined HDP exposure status according to subjects’ first delivery, and only adjusted for  
578 confounders that were assessed prior to cohort entry. Consequently, we were unable to  
579 account for changes in HDP exposure and confounder status over time and did not  
580 assess the cumulative effect of exposure to HDP in subsequent pregnancies on incident  
581 AFib. As such, our effect estimates may be subject to further residual confounding and/or  
582 other time-related bias.<sup>68</sup> However, a few published studies, described as follows, can  
583 provide important insight about the robustness of this approach within our context.

584

585 One recent study<sup>15</sup> reported that the adjusted hazard of arrhythmia for people with a  
586 history of preeclampsia in a first pregnancy was consistent with findings from a sensitivity  
587 analysis wherein preeclampsia was treated a time-dependent variable [adjusted HR (95%  
588 CI): 1.37 (1.23 to 1.54) vs. 1.29 (1.14 to 1.45), respectively]. Additional studies<sup>68, 69</sup> have  
589 also found minimal differences between estimates of CVD risk generated using marginal  
590 structural (time-varying) Cox models compared to those generated using time-fixed  
591 analyses. As such, while the robustness of our findings should be assessed in models  
592 that account for the time-varying nature of HDP and confounders, prior research suggests  
593 that CVD risk may be primarily driven by HDP exposure in a first pregnancy and time-  
594 varying confounding may have a minimal impact on effect estimates.<sup>68</sup>

595

### 596 *Strengths and Limitations*

597 Our large sample size and use of population-based data sources from the most populous  
598 ethnically and culturally diverse province in Canada enhances the generalizability of our  
599 findings. We followed established guidance on the reporting of studies carried out using  
600 routinely collected data,<sup>26</sup> controlled for several important confounders, accounted for the  
601 competing risk of death, and our findings were robust to several sensitivity analyses.

602

603 Although we controlled for a robust set of confounders, we cannot rule out the possibility  
604 that residual confounding may have impacted our results. Pre-pregnancy BMI was  
605 unavailable for nearly 70% of subjects, thus, we adjusted for clinically documented  
606 obesity by identifying ICD-10 codes for this diagnosis in outpatient or inpatient records.  
607 However, individuals with codes for this condition likely only represent extreme cases, so

608 control for this factor was likely incomplete, and may have resulted in spuriously inflated  
609 associations. Despite this, the results of our E-value sensitivity analysis provide some  
610 reassurance about the robustness of our findings to unmeasured confounding.

611  
612 We considered incident chronic hypertension as an intermediate factor in the causal  
613 pathway between HDP and incident AFib and, thus, did not include it in multivariable  
614 models to prevent overadjustment bias.<sup>70</sup> However, given the strong association between  
615 history of chronic hypertension in pregnancy and incident AFib identified in this study, the  
616 shared pathological features of chronic hypertension and AFib (e.g., left ventricular  
617 hypertrophy, diastolic dysfunction),<sup>53</sup> and that incident chronic hypertension post-HDP  
618 was especially prevalent in subjects diagnosed with gestational hypertension (16%) and  
619 preeclampsia (14%), a formal causal mediation analysis<sup>71, 72</sup> should be conducted to  
620 further elucidate the role that post-pregnancy chronic hypertension might play in this  
621 association.

622  
623 **Conclusions**  
624 A history of gestational hypertension, preeclampsia, and chronic hypertension in  
625 pregnancy are each independently associated with a higher csHazard of incident AFib,  
626 with associations observed in relatively young women. Given its rapidly increasing global  
627 prevalence and significant morbidity and mortality burden, AFib has become one of the  
628 most substantial CVD challenges of the 21<sup>st</sup> century— particularly for women. These  
629 findings underscore the critical importance of (a) incorporating information about history  
630 of HDP in risk calculation/stratification for both arrhythmic *and* non- arrhythmic forms of

631 CVD, (b) improved population-based surveillance of traditional and female-specific CVD  
632 risk factors, and (c) the development of targeted prevention strategies designed to reduce  
633 the occurrence, and overall burden, of HDP.

634

### 635 **Acknowledgements**

636 Parts of this material are based on data and/or information compiled and provided by  
637 CIHI, the Ontario Ministry of Health (MOH), and Immigration, Refugees and Citizenship  
638 Canada (IRCC) current to September 2020. The analyses, conclusions, opinions and  
639 statements expressed herein are solely those of the authors and do not reflect those of  
640 the funding or data sources; no endorsement is intended or should be inferred. This  
641 document used data adapted from the Statistics Canada Postal Code<sup>OM</sup> Conversion File,  
642 which is based on data licensed from Canada Post Corporation, and/or data adapted from  
643 the Ontario Ministry of Health Postal Code Conversion File, which contains data copied  
644 under license from ©Canada Post Corporation and Statistics Canada. Adapted from  
645 Statistics Canada, this study used census 2001, 2006, and 2016. This does not constitute  
646 an endorsement by Statistics Canada of this product. We thank the Toronto Community  
647 Health Profiles Partnership for providing access to the Ontario Marginalization Index.

648

### 649 **Sources of Funding**

650 This study was supported by ICES, which is funded by an annual grant from the Ontario  
651 MOH and the Ministry of Long-Term Care. Additional funding was provided by a Canadian  
652 Cardiovascular Society Early Career Arrhythmia and Atrial Fibrillation (ECA3) Grant.

653

654 **Disclosures**

655 When this project was initiated, DBF was employed by the University of Ottawa and had  
656 an academic appointment at the Children's Hospital of Eastern Ontario Research  
657 Institute; although she continues to hold adjunct appointments in both institutions, she is  
658 now employed by Pfizer and works on an unrelated topic. No other authors have any  
659 conflicts of interest to disclose.

660

661

662 **References**

- 663 1. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive  
664 Disorders of Pregnancy Working G. Diagnosis, evaluation, and management of the  
665 hypertensive disorders of pregnancy: executive summary. *J Obstet Gynaecol Can.*  
666 2014;36(5):416-41.
- 667 2. James PR, Nelson-Piercy C. Management of hypertension before, during, and  
668 after pregnancy. *Heart.* 2004;90(12):1499.
- 669 3. Anthony J, Damasceno A, Ojiii D. Hypertensive disorders of pregnancy: what the  
670 physician needs to know. *Cardiovasc J Afr.* 2016;27(2):104-10.
- 671 4. Garovic VD, White WM, Vaughan L, Saiki M, Parashuram S, Garcia-Valencia O,  
672 et al. Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy.  
673 *Journal of the American College of Cardiology.* 2020;75(18):2323-34.
- 674 5. Coutinho T, Lamai O, Nerenberg K. Hypertensive Disorders of Pregnancy and  
675 Cardiovascular Diseases: Current Knowledge and Future Directions. *Curr Treat Options*  
676 *Cardiovasc Med.* 2018;20(7):56.
- 677 6. Wu R, Wang T, Gu R, Xing D, Ye C, Chen Y, et al. Hypertensive Disorders of  
678 Pregnancy and Risk of Cardiovascular Disease-Related Morbidity and Mortality: A  
679 Systematic Review and Meta-Analysis. *Cardiology.* 2020;145(10):633-47.
- 680 7. Johnston A, Smith GN, Tanuseputro P, Coutinho T, Edwards JD. Assessing  
681 cardiovascular disease risk in women with a history of hypertensive disorders of  
682 pregnancy: A guidance paper for studies using administrative data. *Paediatr Perinat*  
683 *Epidemiol.* 2024.

- 684 8. Werlang A, Paquin A, Coutinho T. The EVA Study: Early Vascular Aging in  
685 Women With History of Preeclampsia. *J Am Heart Assoc.* 2023;12(8):e028116.
- 686 9. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al.  
687 Preeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-  
688 Analysis. *Circ Cardiovasc Qual Outcomes.* 2017;10(2).
- 689 10. Al Bahhawi T, Aqeeli A, L Harrison S, A Lane D, Buchan I, Skjoth F, et al.  
690 Pregnancy-related complications and incidence of atrial fibrillation: a systematic review  
691 and meta-analysis. *EP Europace.* 2021;23(Supplement\_3).
- 692 11. Li H, Song X, Liang Y, Bai X, Liu-Huo W-S, Tang C, et al. Global, regional, and  
693 national burden of disease study of atrial fibrillation/flutter, 1990–2019: results from a  
694 global burden of disease study, 2019. *BMC Public Health.* 2022;22(1):2015.
- 695 12. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation:  
696 An increasing epidemic and public health challenge. *Int J Stroke.* 2021;16(2):217-21.
- 697 13. Ray JG, Schull MJ, Kingdom JC, Vermeulen MJ. Heart failure and dysrhythmias  
698 after maternal placental syndromes: HAD MPS Study. *Heart.* 2012;98(15):1136-41.
- 699 14. Park Y, Cho G, Roh S, Na J, Oh M. Increased Cardiac Arrhythmia After  
700 Pregnancy-Induced Hypertension: A South Korean Nationwide Database Study. *J Am*  
701 *Heart Assoc.* 2022;11(2):e023013.
- 702 15. Havers-Borgersen E, Stahl A, Johansen M, Jøns C, Køber L, Fosbøl EL. Pre-  
703 eclampsia and long-term risk of arrhythmias. *European Journal of Preventive*  
704 *Cardiology.* 2024:zwae176.
- 705 16. Leon LJ, McCarthy FP, Direk K, Gonzalez-Izquierdo A, Prieto-Merino D, Casas  
706 JP, et al. Preeclampsia and Cardiovascular Disease in a Large UK Pregnancy Cohort of



- 707 Linked Electronic Health Records: A CALIBER Study. *Circulation*. 2019;140(13):1050-  
708 60.
- 709 17. Oliver-Williams C, Stevens D, Payne RA, Wilkinson IB, Smith GCS, Wood A.  
710 Association between hypertensive disorders of pregnancy and later risk of  
711 cardiovascular outcomes. *BMC Medicine*. 2022;20(1):19.
- 712 18. Auger N, Potter BJ, He S, Healy-Profitos J, Schnitzer ME, Paradis G. Maternal  
713 Cardiovascular Disease 3 Decades After Preterm Birth: Longitudinal Cohort Study of  
714 Pregnancy Vascular Disorders. *Hypertension (Dallas, Tex : 1979)*. 2020;75(3):788-95.
- 715 19. Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, et al. Long-  
716 Term Cardiovascular Risk in Women With Hypertension During Pregnancy. *Journal of*  
717 *the American College of Cardiology*. 2019;74(22):2743-54.
- 718 20. Stuart JJ, Tanz LJ, Rimm EB, Spiegelman D, Missmer SA, Mukamal KJ, et al.  
719 Cardiovascular Risk Factors Mediate the Long-Term Maternal Risk Associated With  
720 Hypertensive Disorders of Pregnancy. *J Am Coll Cardiol*. 2022;79(19):1901-13.
- 721 21. Deshpande S, Catanzaro J, Wann S. Atrial Fibrillation: Prevalence and Scope of  
722 the Problem. *Card Electrophysiol Clin*. 2014;6(1):1-4.
- 723 22. Tan JL, Johnson L, Dziubinski M, Napiorkowski N, Witkowska O, Slusarczyk ME,  
724 et al. Sex differences in presentation of atrial fibrillation: Findings from 30-day  
725 ambulatory monitoring in real-world practice. *American Heart Journal Plus: Cardiology*  
726 *Research and Practice*. 2022;22:100208.
- 727 23. Volgman AS, Benjamin EJ, Curtis AB, Fang MC, Lindley KJ, Naccarelli GV, et al.  
728 Women and atrial fibrillation. *Journal of Cardiovascular Electrophysiology*.  
729 2021;32(10):2793-807.

- 730 24. Kanazawa S, Kaneko H, Yano Y, Suzuki Y, Okada A, Matsuoka S, et al. Sex  
731 Differences in the Association Between Hypertension and Incident Atrial Fibrillation. J  
732 Am Heart Assoc. 2023;12(5):e026240.
- 733 25. Ehdaie A, Cingolani E, Shehata M, Wang X, Curtis AB, Chugh SS. Sex  
734 Differences in Cardiac Arrhythmias. Circulation: Arrhythmia and Electrophysiology.  
735 2018;11(3):e005680.
- 736 26. Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, et al. The  
737 REporting of studies Conducted using Observational Routinely-collected health Data  
738 (RECORD) statement. PLoS Med. 2015;12(10):e1001885.
- 739 27. Matheson F, van Ingen T, Moloney G. 2021 Ontario marginalization index: user  
740 guide. Toronto, ON: St. Michael's Hospital (Unity Health Toronto) and Public Health  
741 Ontario; 2023.
- 742 28. Table 13-10-0429-01 Live births and fetal deaths (stillbirths), by place of birth  
743 (hospital or non-hospital) Ottawa, ON: Statistics Canada; 2023 [Available from:  
744 <https://doi.org/10.25318/1310042901-eng>.
- 745 29. Johnston A, Dancey SR, Tseung V, Skidmore B, Tanuseputro P, Smith GN, et al.  
746 Systematic review of validated case definitions to identify hypertensive disorders of  
747 pregnancy in administrative healthcare databases. Open Heart. 2023;10(2):e002151.
- 748 30. Tu K, Nieuwlaat R, Cheng SY, Wing L, Ivers N, Atzema CL, et al. Identifying  
749 Patients With Atrial Fibrillation in Administrative Data. Can J Cardiol. 2016;32(12):1561-  
750 5.
- 751 31. Jager KJ, Zoccali C, Macleod A, Dekker FW. Confounding: what it is and how to  
752 deal with it. Kidney Int. 2008;73(3):256-60.

- 753 32. Oliver-Williams C, Vassard D, Pinborg A, Schmidt L. Polycystic ovary syndrome  
754 as a novel risk factor for atrial fibrillation: results from a national Danish registry cohort  
755 study. *Eur J Prev Cardiol*. 2020;2047487320922927.
- 756 33. Zahid S, Khan MZ, Gowda S, Faza NN, Honigberg MC, Vaught A, et al. Trends,  
757 Predictors, and Outcomes of Cardiovascular Complications Associated With Polycystic  
758 Ovary Syndrome During Delivery Hospitalizations: A National Inpatient Sample Analysis  
759 (2002–2019). *J Am Heart Assoc*. 2022;11(16):e025839.
- 760 34. Jaimchariyatam N, Na-Rungsri K, Tungsanga S, Lertmaharit S, Lohsoonthorn V,  
761 Totienchai S. Obstructive sleep apnea as a risk factor for preeclampsia-eclampsia.  
762 *Sleep Breath*. 2019;23(2):687-93.
- 763 35. Palma-Reis I, Vais A, Nelson-Piercy C, Banerjee A. Renal disease and  
764 hypertension in pregnancy. *Clin Med (Lond)*. 2013;13(1):57-62.
- 765 36. Choi YJ, Choi EK, Han KD, Park J, Moon I, Lee E, et al. Increased risk of atrial  
766 fibrillation in patients with inflammatory bowel disease: A nationwide population-based  
767 study. *World J Gastroenterol*. 2019;25(22):2788-98.
- 768 37. Jiang L, Tang K, Magee LA, von Dadelszen P, Ekeroma A, Li X, et al. A global  
769 view of hypertensive disorders and diabetes mellitus during pregnancy. *Nat Rev*  
770 *Endocrinol*. 2022;18(12):760-75.
- 771 38. Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA, et  
772 al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific  
773 Statement From the American Heart Association. *Circulation*. 2020;141(16):e750-e72.

- 774 39. Asare AO, Maurer D, Wong AMF, Ungar WJ, Saunders N. Socioeconomic Status  
775 and Vision Care Services in Ontario, Canada: A Population-Based Cohort Study. The  
776 Journal of Pediatrics. 2022;241:212-20.e2.
- 777 40. Inman M, Daneman D, Curtis J, Sochett E, Clarke A, Dunger DB, et al. Social  
778 Determinants of Health Are Associated with Modifiable Risk Factors for Cardiovascular  
779 Disease and Vascular Function in Pediatric Type 1 Diabetes. The Journal of Pediatrics.  
780 2016;177:167-72.
- 781 41. Austin PC. Balance diagnostics for comparing the distribution of baseline  
782 covariates between treatment groups in propensity-score matched samples. Stat Med.  
783 2009;28(25):3083-107.
- 784 42. Austin PC. Using the Standardized Difference to Compare the Prevalence of a  
785 Binary Variable Between Two Groups in Observational Research. Communications in  
786 Statistics - Simulation and Computation. 2009;38(6):1228-34.
- 787 43. Kim MK, Lee SM, Bae S-H, Kim HJ, Lim NG, Yoon S-J, et al. Socioeconomic  
788 status can affect pregnancy outcomes and complications, even with a universal  
789 healthcare system. International Journal for Equity in Health. 2018;17(1):2.
- 790 44. Elin Danielsen L, Albert Marni J, Søren L-C, Kirsten F, Søren Paaske J, Mogens  
791 Lytken L, et al. Socioeconomic position and risk of atrial fibrillation: a nationwide Danish  
792 cohort study. Journal of Epidemiology and Community Health. 2020;74(1):7.
- 793 45. The PHREG Procedure. 2017. In: SAS/STAT® 143 User's Guide [Internet]. Cary,  
794 NC, USA: SAS Institute Inc.
- 795 46. Goldstein L, Ottesen R. Survival 101 - Just Learning to Survive. PharmaSUG  
796 2017; May 14-17; Baltimore, MD2017.

- 797 47. Austin PC, Fang J, Lee DS. Using fractional polynomials and restricted cubic  
798 splines to model non-proportional hazards or time-varying covariate effects in the Cox  
799 regression model. *Stat Med.* 2022;41(3):612-24.
- 800 48. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of  
801 martingale-based residuals. *Biometrika.* 1993;80(3):557-72.
- 802 49. Hosmer D, Lemeshow S, May S. *Applied Survival Analysis : Regression Modeling*  
803 *of Time-to-Event Data.* 2nd ed. New Jersey: John Wiley & Sons, Inc.; 2008.
- 804 50. Harrell FE, Jr. *Regression Modeling Strategies With Applications to Linear*  
805 *Models, Logistic and Ordinal Regression, and Survival Analysis:* Cham: Springer  
806 *InternationalPublishing;* 2015.
- 807 51. Wickham H. *ggplot2: Elegant Graphics for Data Analysis.* New York: Springer-  
808 *Verlag;* 2016.
- 809 52. Al Bahhawi T, Aqeeli A, Harrison SL, Lane DA, Skjøth F, Buchan I, et al.  
810 *Pregnancy-Related Complications and Incidence of Atrial Fibrillation: A Systematic*  
811 *Review.* *J Clin Med.* 2023;12(4):1316.
- 812 53. Bizhanov KA, Abzaliyev KB, Baimbetov AK, Sarsenbayeva AB, Lyan E. Atrial  
813 *fibrillation: Epidemiology, pathophysiology, and clinical complications (literature review).*  
814 *J Cardiovasc Electrophysiol.* 2023;34(1):153-65.
- 815 54. Östlund E, Al-Nashi M, Hamad RR, Larsson A, Eriksson M, Bremme K, et al.  
816 *Normalized endothelial function but sustained cardiovascular risk profile 11 years*  
817 *following a pregnancy complicated by preeclampsia.* *Hypertens Res.* 2013;36(12):1081-  
818 7.

- 819 55. Segers VFM, Brutsaert DL, De Keulenaer GW. Cardiac Remodeling: Endothelial  
820 Cells Have More to Say Than Just NO. *Front Physiol.* 2018;9:382.
- 821 56. van Rijn BB, Bruinse HW, Veerbeek JH, Post Uiterweer ED, Koenen SV, van der  
822 Bom JG, et al. Postpartum Circulating Markers of Inflammation and the Systemic Acute-  
823 Phase Response After Early-Onset Preeclampsia. *Hypertension.* 2016;67(2):404-14.
- 824 57. Korantzopoulos P, Letsas KP, Tse G, Fragakis N, Goudis CA, Liu T. Inflammation  
825 and atrial fibrillation: A comprehensive review. *J Arrhythm.* 2018;34(4):394-401.
- 826 58. Yinon Y, Kingdom JC, Odutayo A, Moineddin R, Drewlo S, Lai V, et al. Vascular  
827 dysfunction in women with a history of preeclampsia and intrauterine growth restriction:  
828 insights into future vascular risk. *Circulation.* 2010;122(18):1846-53.
- 829 59. Orabona R, Sciatti E, Vizzardi E, Bonadei I, Valcamonico A, Metra M, et al.  
830 Endothelial dysfunction and vascular stiffness in women with previous pregnancy  
831 complicated by early or late pre-eclampsia. *Ultrasound Obstet Gynecol.* 2017;49(1):116-  
832 23.
- 833 60. Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, et al. Preeclampsia  
834 and Future Cardiovascular Disease: Potential Role of Altered Angiogenesis and Insulin  
835 Resistance. *The Journal of Clinical Endocrinology & Metabolism.* 2004;89(12):6239-43.
- 836 61. Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in  
837 pregnancy and later cardiovascular risk: common antecedents? *Circulation.*  
838 2010;122(6):579-84.
- 839 62. Schuster NA, Hoogendijk EO, Kok AAL, Twisk JWR, Heymans MW. Ignoring  
840 competing events in the analysis of survival data may lead to biased results: a

- 841 nonmathematical illustration of competing risk analysis. *Journal of Clinical*  
842 *Epidemiology*. 2020;122:42-8.
- 843 63. Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the  
844 Presence of Competing Risks. *Circulation*. 2016;133(6):601-9.
- 845 64. Abdel-Qadir H, Fang J, Lee DS, Tu JV, Amir E, Austin PC, et al. Importance of  
846 Considering Competing Risks in Time-to-Event Analyses: Application to Stroke Risk in a  
847 Retrospective Cohort Study of Elderly Patients With Atrial Fibrillation. *Circulation*  
848 *Cardiovascular quality and outcomes*. 2018;11(7):e004580-e.
- 849 65. Welters SM, de Boer M, Teunissen PW, Hermes W, Ravelli ACJ, Mol BW, et al.  
850 Cardiovascular mortality in women in their forties after hypertensive disorders of  
851 pregnancy in the Netherlands: a national cohort study. *The Lancet Healthy Longevity*.  
852 2023;4(1):e34-e42.
- 853 66. Langlois AWR, Park AL, Lentz EJM, Ray JG. Preeclampsia Brings the Risk of  
854 Premature Cardiovascular Disease in Women Closer to That of Men. *The Canadian*  
855 *journal of cardiology*. 2020;36(1):60-8.
- 856 67. DeRoo LA. Hypertensive Disorders in Pregnancy and Future  
857 Maternal Cardiovascular Disease: The Challenges of Looking Beyond First Pregnancy.  
858 *Paediatr Perinat Epidemiol*. 2017;31(5):422-3.
- 859 68. Grandi SM, Vallée-Pouliot K, Reynier P, Eberg M, Platt RW, Arel R, et al.  
860 Hypertensive Disorders in Pregnancy and the Risk of Subsequent Cardiovascular  
861 Disease. *Paediatr Perinat Epidemiol*. 2017;31(5):412-21.

- 862 69. Grandi SM, Reynier P, Platt RW, Basso O, Filion KB. The timing of onset of  
863 hypertensive disorders in pregnancy and the risk of incident hypertension and  
864 cardiovascular disease. *Int J Cardiol.* 2018;270:273-5.
- 865 70. van Zwieten A, Tennant PWG, Kelly-Irving M, Blyth FM, Teixeira-Pinto A,  
866 Khalatbari-Soltani S. Avoiding overadjustment bias in social epidemiology through  
867 appropriate covariate selection: a primer. *Journal of Clinical Epidemiology.*  
868 2022;149:127-36.
- 869 71. VanderWeele TJ. Causal mediation analysis with survival data. *Epidemiology*  
870 (Cambridge, Mass). 2011;22(4):582-5.
- 871 72. Tyler V. *Explanation in Causal Inference : Methods for Mediation and Interaction.*  
872 New York: Oxford University Press; 2015.
- 873 73. Nakazawa M. *Functions for Medical Statistics Book with some Demographic*  
874 *Data.* 0.7.6 ed2024.
- 875



876 **Tables**

877 Table 1. Baseline maternal characteristics at study entry.

	<b>Total</b>	<b>No HDP</b>	<b>HDP</b>	<b>ASD (%)</b>
Total No. Study Subjects (%)	771,521 (100)	710,035 (92.0)	61,486 (8.0)	--
<b>Maternal Characteristics</b>				
<b>Age at First Delivery, Years</b>				
Median (Q1-Q3)	29 (25-32)	29 (25-32)	29 (26-33)	<b>13</b>
<b>Age Group (Years)</b>				
<20	34,697 (4.5)	32,613 (4.6)	2,084 (3.4)	5
20 to 24	132,764 (17.2)	123,448 (17.4)	9,316 (15.2)	2
25 to 29	250,841 (32.5)	231,439 (32.6)	19,402 (31.6)	6
30 to 34	244,567 (31.7)	225,397 (31.7)	19,170 (31.2)	6
35 to 39	90,178 (11.7)	81,204 (11.4)	8,974 (14.6)	2
40 to 44	17,258 (2.2)	14,976 (2.1)	2,282 (3.7)	1
45 to 49	1,117 (0.1)	889 (0.1)	228 (0.4)	9
50+	99 (0.01)	69 (0.01)	30 (0.05)	<b>10</b>
<b>Comorbid Conditions*</b>				
Diabetes Mellitus	11,296 (1.5)	8,828 (1.2)	2,468 (4.0)	<b>17</b>
Polycystic Ovary Syndrome	26,192 (3.4)	23,229 (3.3)	2,963 (4.8)	8
Sleep Apnea**	15,148 (2.0)	13,102 (1.8)	2,046 (3.3)	9
Ever Smoker	23,730 (3.1)	21,676 (3.1)	2,054 (3.3)	2
Kidney Disease	18,337 (2.4)	16,060 (2.3)	2,277 (3.7)	9
Chronic Immune-Mediated Inflammatory Conditions†	16,569 (2.1)	14,942 (2.1)	1,627 (2.6)	4
Obesity	2,359 (0.3)	1,788 (0.3)	571 (0.9%)	9
Baseline Hypertension	16,715 (2.2)	9,737 (1.4)	6,978 (11.3%)	<b>42</b>
<b>Sociodemographic Characteristics</b>				
Immigrant††	159,375 (20.7)	149,546 (21.1%)	9,829 (16.0%)	<b>13</b>
<b>Rurality Index of Ontario (RIO2008)*</b>				
Urban	579,948 (75.2)	536,410 (75.5)	43,538 (70.8)	<b>11</b>
Suburban	140,165 (18.2)	126,912 (17.9)	13,253 (21.6)	9
Rural	47,714 (6.2)	43,371 (6.1)	4,343 (7.1)	4
Missing	3,694 (0.5)	3,342 (0.5)	352 (0.6)	1

<b>ON-Marg Dimension</b>				
<b>Age and Labour Force Dimension</b>				
Quintile 1	250,642 (32.5)	231,223 (32.6)	19,419 (31.6)	2
Quintile 5	103,732 (13.4)	94,977 (13.4)	8,755 (14.2)	3
<b>Material Resources Dimension</b>				
Quintile 1	166,892 (21.6)	153,917 (21.7)	12,975 (21.1)	1
Quintile 5	158,854 (20.6)	145,886 (20.5)	12,968 (21.1)	1
<b>Households and Dwellings Dimension</b>				
Quintile 1	149,548 (19.4)	138,366 (19.5)	11,182 (18.2)	3
Quintile 5	184,498 (23.9)	170,461 (24.0)	14,037 (22.8)	3
<b>Racialized and Newcomer Populations Dimension</b>				
Quintile 1	106,365 (13.8)	96,557 (13.6)	9,808 (16.0)	7
Quintile 5	234,329 (30.4)	218,336 (30.8)	15,993 (26.0)	<b>11</b>
<b>Visible Minority Quintile</b>				
Quintile 1	161,174 (20.9)	146,182 (20.6)	14,992 (24.4)	9
Quintile 5	125,948 (16.3)	117,881 (16.6)	8,067 (13.1)	10
Missing	3,960 (0.5)	3,684 (0.5)	276 (0.4)	1

878 *Note: Values are n (%) unless otherwise noted. An ASD >10% (**bold**) was interpreted as a potentially meaningful difference in a*  
879 *baseline characteristic between groups.*

880 *ASD= absolute standardized difference, SD= standard deviation, ON-Marg = Ontario Marginalization Index, OHIP = Ontario Health*  
881 *Insurance Program, IRCC = Immigration, Refugee, and Citizenship Canada, Q= quartile*

882 *† Composite variable that includes subjects diagnosed with ≥1 of the following conditions prior to cohort entry: lupus, inflammatory*  
883 *bowel disease, psoriatic arthritis, ankylosing spondylitis, and/or rheumatoid arthritis.*

884 *\*RIO2008 categorized as Urban = RIO < 10, Suburban = RIO 10–39, Rural = RIO ≥ 40*

885 *\*\*Proxy variable based on having ≥1 OHIP code for sleep study.*

886 *†† Has an IRCC landing date*

887

888 Table 2. Total number of events, person-years of follow-up, cause-specific incidence rates, and incidence rate ratios for  
 889 incident atrial fibrillation and all-cause mortality without a prior atrial fibrillation diagnosis by any hypertensive disorder of  
 890 pregnancy and individual subtypes.

	Exposure							
	Not Exposed	Any HDP	Gestational Hypertension	Chronic Hypertension	Preeclampsia	Superimposed Preeclampsia	Eclampsia	Unspecified
<b>Incident Atrial Fibrillation</b>								
Total events	2,187	<300*	178	30	65	<10*	<10*	10
Total PY of follow-up	6,797,092	583,212	393,969	29,456	123,329	10,022	9,207	17,229
csIR per 10,000 PY (95% CI)	3.2 (3.1-3.3)	5.1 (4.6-5.6)	4.5 (4.0 - 5.1)	10.2 (7.1-13.2)	5.3 (4.2-6.4)	*	*	5.8 (2.8-8.8)
csIRR (95% CI)	<b>Reference</b>	1.58 (1.40-1.78)	1.40 (1.21-1.64)	3.17 (2.21-4.54)	1.64 (1.28-2.10)	*	*	1.80 (0.97-3.36)
<b>All-cause Mortality without a Prior Atrial Fibrillation Diagnosis</b>								
Total events	2,631	320	181	32	73	12	8	14
Total PY of follow-up	6,797,092	583,212	393,969	29,456	123,329	10,022	9,207	17,229
csIR per 10,000 PY (95% CI)	3.9 (3.8-4.0)	5.5 (5.0-6.0)	4.6 (4.0-5.2)	10.9 (7.7-14.0)	5.9 (4.8-7.1)	12.0 (6.3-17.7)	8.7 (3.6-13.7)	8.1 (4.6-11.7)
csIRR (95% CI)	<b>Reference</b>	1.42 (1.26-1.59)	1.19 (1.02-1.38)	2.81 (1.98-3.98)	1.53 (1.21-1.93)	3.09 (1.75-5.45)	2.24 (1.12-4.49)	2.10 (1.24-3.55)

891

892 *Abbreviations: PY = person-years, CS= cause-specific, CI = confidence interval, IR = incidence rate, HR = hazard ratio*

893 *All calculations made using the fmsb package (v.0.7.6)<sup>73</sup> in RStudio (v. 2023.12.1.402).*

894 *\* Data suppressed due to small numbers to comply with ICES privacy requirements*

895

896

897 Table 3. Cause-specific multivariable adjusted hazard ratios (95% confidence intervals) for incident atrial fibrillation and all-  
 898 cause mortality without a prior atrial fibrillation diagnosis.

Incident Atrial Fibrillation						
	Gestational Hypertension**	Preeclampsia	Eclampsia	Unspecified	Superimposed Preeclampsia	Chronic Hypertension in Pregnancy
<b>Adjusted* csHR (95% CI)</b>	<b>1.49 (1.25-1.78)</b>	<b>1.53 (1.20-1.96)</b>	1.55 (0.64-3.72)	1.66 (0.89-3.09)	1.70 (0.84-3.43)	<b>2.24 (1.55-3.23)</b>
All-Cause Mortality Without a Prior Atrial Fibrillation Diagnosis						
	Gestational Hypertension	Preeclampsia	Eclampsia	Unspecified	Chronic Hypertension in Pregnancy	Superimposed Preeclampsia
<b>Adjusted* csHR (95% CI)</b>	1.13 (0.97-1.31)	<b>1.43 (1.13-1.81)</b>	1.91 (0.95-3.82)	<b>1.91 (1.13-3.23)</b>	<b>2.04 (1.43-2.91)</b>	<b>2.12 (1.20-3.78)</b>

899 *Abbreviations: CS= cause-specific, CI = confidence interval*

900 \* All cause-specific hazard ratios adjusted for age at delivery, diabetes mellitus, polycystic ovary syndrome, sleep apnea, smoking,  
 901 kidney disease, obesity, chronic immune-mediated conditions, and material resources (ON-Marg material resources dimension  
 902 quintiles). **Bolded** estimates indicate statistical significance.


903 \*\* A time-segmented analysis was undertaken in these models whereby follow-up time for events was restricted to >4.5 years post  
 904 index delivery, as the PH assumption held for this follow-up period.

905  
 906  
 907

908

909

910 **Figures**




911

912 Figure 1. Flow diagram illustrating the selection of study subjects.

913

914




915  
916 Figure 2. Proportion of study subjects (per 1,000 deliveries) diagnosed with a  
917 hypertensive disorder of pregnancy during the study's exposure accrual period, by  
918 subtype. For each HDP subtype, the numerator included the total number of subjects  
919 diagnosed with that specific subtype during the study period and the denominator  
920 included the total number of study subjects.

921

922

923

924




925

926 Figure 3. Median number of years to incident atrial fibrillation and all-cause mortality in  
927 study subjects diagnosed with a hypertensive disorder of pregnancy, overall and by  
928 exposure subtype.

929 *Note: Results for eclampsia should be interpreted with caution due to the low number of events in*  
930 *subjects diagnosed with this HDP subtype (n <10).*

931  
932




933

934 Figure 4. Cause-specific cumulative incidence curves for atrial fibrillation (outcome) and  
935 all-cause mortality (competing risk) stratified by hypertensive disorder of pregnancy  
936 exposure status (first obstetrical delivery).

937

938





939 Figure 5. Cause-specific multivariable adjusted hazard ratios and accompanying 95% confidence intervals (log-scale), for  
 940 atrial fibrillation (A) and all-cause mortality (B) by any hypertensive disorder of pregnancy and each subtype.

941 *Note: Hazard ratios adjusted for maternal age at delivery, diabetes mellitus, polycystic ovary syndrome, sleep apnea, smoking, kidney disease,*  
 942 *obesity, chronic immune-mediated conditions, and ON-Marg material resources dimension (quintiles).*

943 **Supplemental Material**

944 Data Supplement S1-S8

945 Tables S1–S7

946 Figures S1-S5

947 References 1-22

948

949

950

951

952

953